MedTrace Logo

The INSPIRE-ASP PNA Trial

NCT03697070 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 44780

Last updated 2025-01-29

Study results available
· View outcomes & findings →

Summary

The INSPIRE-ASP PNA trial is a cluster-randomized controlled trial of HCA hospitals comparing routine empiric antibiotic stewardship practices with real-time precision medicine computerized physician order entry smart prompts providing the probability that a non-critically ill adult admitted with PNA is infected with a resistant pathogen.

Note: that enrolled "subjects" represents 59 individual HCA hospitals that have been randomized.

Conditions

Interventions

OTHER

INSPIRE CPOE Smart Prompt

Quality improvement intervention: computerized physician order entry (CPOE) decision support alert that provides physicians with patient-specific risk estimate of having PNA due to a multidrug resistant organism (MDRO) and recommends appropriate antibiotic choice for non-ICU patients in the first 3 days of hospitalization. Continuation of other antibiotic stewardship activities in accordance with national standards.

OTHER

Routine Care

Routine Antibiotic Stewardship Arm - Continuation of all antibiotic stewardship activities in accordance with national standards.

Sponsors & Collaborators

  • Hospital Corporation of America

    collaborator INDUSTRY

  • University of California, Irvine

    collaborator OTHER

  • University of Massachusetts, Amherst

    collaborator OTHER

  • Brigham and Women's Hospital

    collaborator OTHER

  • Centers for Disease Control and Prevention

    collaborator FED

  • Harvard Pilgrim Health Care

    lead OTHER

Principal Investigators

  • Shruti Gohil, MD, MPH · UC Irvine Div Infectious Diseases

  • Susan Huang, MD, MPH · UC Irvine Div Infectious Diseases

  • Richard Platt, MD, MS · Harvard Pilgrim Health Care Institute

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-01
Primary Completion
2024-05-16
Completion
2024-05-16

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03697070 on ClinicalTrials.gov